Tag: critical limb ischemia
Government Grand Rounds: Educating through advocacy
Since the initial launch of the Cancer Moonshot in 2016, the cancer community has made tangible progress towards ambitious goals, including accelerating scientific discovery...
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66%...
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint...
BEST-CLI attracts $3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a $3.3 million contribution toward the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb...
CLTI: Translating guidelines into practice
Clinical practice guidelines (CPG) are integral to helping achieve optimal patient care. The Society for Vascular Surgery (SVS) clinical guidelines are evidence-based and the...
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery...
Journal of Critical Limb Ischemia set to launch in spring
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new title, Journal...
FDA panel recommends against premarket approval of Lutonix 014 DCB for...
A Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in below-the-knee (BTK) arteries....
First US commercial use of Tack Endovascular System in BTK arteries...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the United States.
Notably the first Food...
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...